Biohaven Ltd. (NYSE:BHVN) Director Purchases $996,369.00 in Stock

Biohaven Ltd. (NYSE:BHVN) Director John W. Childs bought 32,700 shares of the company’s stock in a transaction on Tuesday, March 4th. The shares were acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the acquisition, the director now directly owns 2,320,571 shares of the company’s stock, valued at $70,707,798.37. This trade represents a 1.43 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Biohaven Stock Performance

BHVN opened at $31.12 on Wednesday. The stock’s fifty day moving average is $38.16 and its 200-day moving average is $42.71. Biohaven Ltd. has a one year low of $26.80 and a one year high of $62.21. The company has a market capitalization of $3.15 billion, a PE ratio of -3.31 and a beta of 1.27.

Biohaven (NYSE:BHVN) last issued its earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). On average, equities research analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Deutsche Bank Aktiengesellschaft initiated coverage on Biohaven in a research note on Tuesday, February 11th. They issued a “buy” rating and a $65.00 target price for the company. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price objective on shares of Biohaven in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $54.00 target price on shares of Biohaven in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a report on Tuesday, December 17th. Finally, TD Cowen upped their target price on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Fourteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $62.77.

Institutional Trading of Biohaven

A number of hedge funds have recently made changes to their positions in the stock. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Biohaven in the 4th quarter valued at approximately $449,000. Infinitum Asset Management LLC acquired a new stake in Biohaven in the fourth quarter valued at approximately $4,108,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Biohaven by 7.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 548,575 shares of the company’s stock worth $20,489,000 after acquiring an additional 39,953 shares in the last quarter. TrinityPoint Wealth LLC bought a new position in shares of Biohaven during the 4th quarter valued at $1,385,000. Finally, Suvretta Capital Management LLC boosted its holdings in Biohaven by 8.1% in the fourth quarter. Suvretta Capital Management LLC now owns 5,620,271 shares of the company’s stock worth $209,917,000 after purchasing an additional 421,052 shares in the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.